Tag Archives: transcatheter aortic valve replacement

The evidence supporting early discharge after TAVI Patients discharged early from hospital generally have a reduced risk of the physical and functional consequences associated with immobilisation and longer hospital stay, including hospital-acquired infections, functional dependency and cognitive decline.13,14 Elderly and frail patients are at risk of hospital-associated complications and are most likely to benefit from a shorter hospital stay.7,14 In the context of TAVI, the feasibility and safety of early discharge are well established.6–10,15 As early as 2015, early discharge was shown to be feasible and safe in approximately 80% of pat

Discussion Biomarkers have not been used routinely in clinical AS management, but recent advances look set to change this. The PROGRESSA (Metabolic Determinants of the Progression of Aortic Stenosis) study identified that a higher ratio of apolipoprotein B/apolipoprotein A‐I was associated with a 3.4-fold increase in haemodynamic progression in the younger (<70 years) AS cohort. The balance of atherogenic and anti-atherogenic lipid factors appears to play a crucial role in pathogenesis in younger patients,4 presenting a screening target. Regardless of symptom status, biomarkers have application in risk stratification. Systematic review

Introduction Systolic heart failure (SHF) in patients with severe aortic stenosis (AS) carries a worse prognosis, and aortic valve replacement improves ventricular systolic function and survival.1,2 Therefore, SHF is an indication for aortic valve replacement in severe AS.2 Both surgical aortic valve replacement (SAVR) and transcatheter aortic valve replacement (TAVR) are associated with comparable survival and ventricular systolic function recovery in this group of patients.3 TAVR, however, is the recommended approach for patients with intermediate to prohibitive surgical risk; and SHF patients are often considered a high-risk group. As a re

SAPIEN valve positive results Clinicians have achieved successful one-year outcomes in high-risk or inoperable patients undergoing transcatheter aortic valve replacement during the first two years since release of the valve (Sapien®, Edwards) commercially, according to results presented at the Euro PCR 2001 meeting in Paris, France. Despite high predicted mortality and multiple co-morbidities in many of these patients, survival at one year was 76% in the 1,038 patients treated as part of Cohort I (first year of commercialisation), and 77% in the 1,269 patients treated as part of Cohort II (second year of commercialisation).  Since November